BioCentury
DATA GRAPHICS | Product Development

Over 100 Phase III readouts from COVID-19 therapies possible by 2Q21: Data Byte

Antiparasitics, immunosuppressants and antivirals top the list of molecular classes for COVID-19 therapies

December 3, 2020 12:10 AM UTC

Against the backdrop of excitement for COVID-19 vaccines, clinical trials of treatments for infected patients have been mounting. Public databases list 252 Phase III trials of treatments for COVID-19, of which only 25 (10%) had read out as of Nov. 30.

Fifty-six of these trials have completion dates between now and the end of 1Q21, and 87 additional trials recently passed their estimated completion date, suggesting some of them will report data soon. The question is how many...